<DOC>
	<DOCNO>NCT01081132</DOCNO>
	<brief_summary>To assess efficacy optimize Extended-release Guanfacine Hydrochloride compare placebo treatment adolescent age 13-17 year diagnosis ADHD measure ADHD-RS-IV</brief_summary>
	<brief_title>Dose-optimization Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder ( ADHD ) Using Extended-release Guanfacine HCl</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>1 . Male female , age 1317 year time consent/assent ( screen ) . 2 . Subject 's parent legally authorize representative ( LAR ) must provide signature informed consent , must documentation assent subject indicate subject aware investigational nature study require procedure restriction accordance International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) Guidance E6 ( 1996 ) applicable regulation complete studyrelated procedure screen . 3 . Subject meet Diagnostic Statistical Manual Mental Disorders , Fourth EditionText Revision ( DSMIVTR ) criteria primary diagnosis ADHD , combine subtype , hyperactive/impulsive subtype , base detailed psychiatric evaluation use Kiddie Schedule Affective Disorders Schizophrenia Present Lifetime version ( K SADS PL ) screening ( reconfirm baseline visit &gt; 35 day screen ) . 4 . Subject minimum ADHDRSIV total score 32 baseline . 5 . Subject minimum CGIS score 4 baseline . 6 . Subject function ageappropriate level intellectually , deem Investigator . 7 . Subject parent/LAR understand , able , willing likely fully comply study procedure restriction define protocol . 8 . Subject able swallow intact tablet . 9 . All female must negative serum beta human Chorionic Gonadotropin ( hCG ) pregnancy test screen negative urine pregnancy test baseline . Female subject must abstain sexual activity could result pregnancy agree use acceptable method contraception . 10 . Subject supine stand blood pressure ( BP ) measurement within 95th percentile age , gender , height . 1 . Subject current , control ( require prohibit medication behavioral modification program ) uncontrolled , comorbid psychiatric diagnosis [ except Oppositional Defiant Disorder ( ODD ) , include anxiety disorder ( except simple phobia ) ] , major depressive disorder ( dysthymia allow unless medication require ) , severe comorbid Axis II disorder severe Axis I disorder post traumatic stress disorder , bipolar illness , psychosis , pervasive developmental disorder , obsessivecompulsive disorder , substance abuse disorder , symptomatic manifestation , opinion Investigator , contraindicate SPD503 treatment confound efficacy safety assessment . 2 . Subject condition illness include clinically significant abnormal screen laboratory value , opinion Investigator , represent inappropriate risk subject and/or could confound interpretation study . 3 . Subject known history presence structural cardiac abnormality , serious heart rhythm abnormality , syncope , cardiac conduction problem ( e.g. , clinically significant heart block ) , exerciserelated cardiac event include syncope presyncope , clinically significant bradycardia . 4 . Subject abnormal clinically significant ECG finding judge Investigator consideration central ECG interpretation . 5 . Subject orthostatic hypotension know history control uncontrolled hypertension . 6 . Current use prohibit medication , include herbal supplement affect blood pressure , heart rate , central nervous system ( CNS ) effect , affect cognitive performance , sedate antihistamine decongestant sympathomimetics ( inhaled bronchodilator permit ) history chronic use sedate medication ( i.e. , antihistamine ) baseline . 7 . Subject history alcohol substance abuse dependence , define DSM IVTR ( exception nicotine ) within last six month . 8 . Subject take another investigational product within 30 day prior baseline . 9 . Subject significantly overweight base Center Disease Control Prevention Body Mass Index ( BMI ) forage gender specific chart screen . Significantly overweight define BMI &gt; 95th percentile study . 10 . Body weight less 34.0kg great 91.0kg screening . 11 . Subject know suspected allergy , hypersensitivity , clinically significant intolerance guanfacine hydrochloride component find SPD503 . 12 . Clinically important abnormality urine drug and/or alcohol screen ( exclude subject 's current ADHD stimulant applicable ) . 13 . Subject female pregnant currently lactate . 14 . Subject fail screen previously enrol study . 15 . Subject currently consider suicide risk , previously make suicide attempt , prior history , currently demonstrate suicidal ideation . 16 . History failure respond adequate trial ( consist appropriate dose adequate duration therapy ) , opinion Investigator , Î±2agonist treatment ADHD . 17 . Subject history seizure disorder ( single childhood febrile seizure occur age 3 year ) history tic disorder ( include Tourette 's syndrome ) .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>